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Abstract:  
Nasopharyngeal carcinoma (NpC) is a malignant disease associated with Epstein-Barr virus infection, and often diagnosed at an 
advanced stage. This significantly curtails patient survival. We hypothesize that a panel of biomarkers can be assembled to assess 
NpC incidence, early detection, and tumor progression during therapeutic intervention. Our thesis rests on a model of 
successfully predicting high-risk gliomas by means of a carefully crafted panel of molecular mitotic biomarkers (i.e., securin, 
survivin and MCM2). The strategy we propose holds strong promise for prevention and cure of NpC. The approach we propose 
seeks to identify certain biomarkers from viral materials, patient tissues and assessment of related diseases, whose signatures, 
taken together, will be endowed with some degree of congruency, or sense of a coordinated language (i.e., “votes”).  Biomarker 
“voting” will then permit to outline a broad coordinated molecular map for the molecular and epigenetic characterization of each 
individual patient’s NpC tumor. We will draw on the process of contrasting biomarkers in health and disease, which rests on the 
auto-proteomic concept particularly relevant in high-risk cancer individuals, such as is the case for NpC. In brief we defend, 
current advances in human proteome profiling proffers the possibility of having individual baseline proteomic profiles using local 
body fluids (e.g., saliva, nasal secretions, sputum) or systemic fluids (e.g., plasma, serum, cerebrospinal fluid) to unravel a 
personalized molecular map for high-risk NpC individuals.  Regular check-up will monitor for new or impending manifestations 
of NpC, and provide a secure assessment of incidence and early detection. 
 
Keywords: Molecular & Epigenetic Biomarkers, Nasopharyngeal carcinoma, Translational evidence-based personalized 
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Background:  
Nasopharyngeal carcinoma (NpC) is a malignant tumor 
mostly of the lateral wall of the nasopharnyx. NpC has 
multifactorial etiological factors, including genetic, 
environmental, and Epstein-Barr (EBV; human herpesvirus-
4, HHV-4) infections [1, 2]. NpC has a significant 
geographical distribution [3], being most common among 
Asians, particularly the adult population of Southeastern Asia 
(prevalence: 15-50/100,000, 37) [1, 2] and North African 
(prevalence: 15-50/100,000, 37) [1, 2]. In Africa, NpC is the 
most frequent childhood cancer.  Whereas prevalence of NpC 
is generally 2:1 higher in males, compared to females [1, 37], 
increased risk for NpC is associated with specific class I 
human leukocyte antigens (HLA-1) haplotypes. across 
genders (12,13): HLA-2, HLA-B17, and HLA-Bw26 
haplotypes double the risk of NpC, as well as epigenetic 
aberrations in chromosomes 1, 3 , 9,  11, 12, and 14 [37]. 
 
Diet plays an important role in individuals at high-risk for 
NpC. Regular consumption of salted fish, particularly from 
an early age onward [5, 12, 15, 17, 18], and consumption of 
preserved foods [19] increase incidence.  Exposure to 
cigarette smoking and other sources of nitrosamine [5] as 
well as to polycyclic hydrocarbons also increase risk for 
NpC.  Chronic nasal infections, poor oro-nasal hygiene, 
inadequate nasopharynx ventilation, and improper use of 
certain herbal teas, concoctions and medicines, such as 
intranasal oils, have all been reported to predispose NpC 
development [5, 14, 16]. 
 
The nasopharynx is composed of stratified squamous cells, 
pseudostratified columnar ciliated cells, and patches of some 
intermediate cells (1). Histopathologically, NpC takes one of 
three patterns: (1) keratinizing squamous cell carcinomas 
(type I), (2) non keratinizing squamous cell carcinoma (type 
II), or (3) undifferentiated carcinomas (type III) with 
abundant non-neoplastic lymphocytic infiltrate [1-3] of 
putative tumor-directed cytotoxic CD8+CD38+ tumor-
infiltrating lymphocytes (i.e., TIL). 
 
A DNA Herpes virus that targets B lymphocytes by binding 
its viral envelope glycoprotein (gp350) to the complement 
component-3d receptor 2 (CR2, CD21), and its gp42 to the 
leukocyte antigen, HLA [5], EBV infects and persists in the 
latent form preferentially in B cells [10]. The virus, first 
isolated in Uganda in 1964, is associated with several cancers 
besides NpC, including gastric carcinoma, B cell lymphomas 
(e.g., Hodgkin’s and Burkitt’s lymphomas) [5, 29], and a 
subset of T cell lymphoma [20].  EBV is also implicated in 
infectious mononucleosis [21].  
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The EBV genome occurs in the epithelial cells of most type 
II and III carcinomas [3, 4], and its latent membrane protein 
(LMP)-1, the main viral transforming protein, has pleitrophic 
effects in eukaryotic cells that range from increase signaling 
through the TNF-α/CD40 pathway, induction of anti-
apoptotic proteins, increase cell surface adhesions, and 
expression of certain cytokine genes [5-9].  LMP2A, but not 
LMP2B can (1) favor survival and proliferation of B cells in 
the absence of signaling through the B cell receptor, (2) 
transform epithelial cells and  enhance their adhesion and 
motility in part through the PI3K pathway [5, 11], and (3) 
increase genes involved in cell cycle induction, inhibition of 
apoptosis and suppression of cell mediated immunity [5]. 
 
We propose the hypothesis that the occurrence and 
progression of NpC can be predicted by assessing a panel of 
molecular and epigenetic biomarkers.  A corollary hypothesis 
states that a proteome profiling such as that proposed in 
Schemes 1A-1C (see supplementary material) of local (e.g., 
saliva) or systemic body fluids (e.g., plasma) may yield a 
personalized molecular map for high-risk NpC individuals, 
and that regular check-up will permit monitoring for new or 
impending manifestations of NpC. 
 
 
Figure 1: Panel A: Survival graph of glioma patients (control-8 and selected-30) reference by age (55 years): This figure 
show that group 1 patient (≥55 years) had worse survival compared to group 2 patient (< 55years). The age 55years was used as a 
reference based on evidences in the literature and the median age estimate of patients used in this study. Survival graph was 
generated by input of the survival data in the SAS statistical software (X
2, p=0.1241). Panel B: Survival graph of the 38 high 
risk glioma patients based on positivity for number of markers: Thirty (30) selected and eight (8) control patients were 
assessed based on the positivity for the four mitotic markers. The control patients were determined to be high risks group 2a 
prognostic members (see reference 22) by gene microarray studies. This figure shows that patients that were high risk and 
positive for two markers (Group 1) or three markers (Group 2) have similar survival pattern and tend to live longer than those 
patients that are high risks and positive for the four markers (Group 3). Survival distribution graph was generated by input of the 
survival data in the SAS statistical software (X
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Methodology:   
A panel of molecular and epigenetic biomarkers can be 
designed, generated and tested with the specific intent of 
assessing NpC incidence, early detection, and tumor 
progression during therapeutic intervention. The rationale for 
this methodology rests on current understanding that 
regulation of genes, including oncogenes and tumor 
suppressor genes, is associated with heritable traits encoded 
directly in the genome.   
 
Heritable non-encoded aspects of the genome can control and 
modify gene expression. Such epigenetic modifications are 
passed down the cell progeny, though not directly encoded in 
the genomic structure.  They, nonetheless, alter the physical 
availability of genes to transcriptional machinery.  Epigenetic 
modifications, including DNA methylation and histone 
acetylation, can therefore exert modulatory control over the 
expression of certain oncogenes and tumor suppressor genes.  
This is typically obtained by modification of the chromatin 
architecture, assembly and repair events, which result in open 
"euchromatin" or closed "heterochromatin" states [38].  
 
A model of successfully predicting high-risk gliomas by 
means of a carefully crafted panel of molecular mitotic 
biomarkers (i.e., securin, survivin, topoisomerase-II alpha 
[TOP2A], and minichromosome maintenance-2 [MCM2]), 
and the resulting protein votes of molecular mitotic 
signatures (cf., Figure 1a & 1b) demonstrates that high 
expressions of at least two of these markers were pooled 
together as protein votes to identify very high-risk glioma 
patients belonging to Group 2a prognostic group [22]. The 
panel of biomarkers, which consist of securin, survivin an 
anti-apoptotic protein and MCM2, was found to be reliably 
effective in the identification of high-risk patients with 
molecular signatures similar to that of control patients, who 
were established to have the known high-risk Group 2a 
prognosis, based on the traditional gene microarray analysis 
(Figure 1a & 1b). 
 
In the case of NpC, we propose a methodology directed at the 
assessment of a panel of biomarkers designed to predict 
patients at high-risk for NpC.  We project that the panel will 
involve, in addition to the traditional patho-anatomical 
assessment of masses and enlarged drainage lymph nodes, 
certain molecular and epigenetic markers consequential to 
EBV infection (e.g., anti EBV antibodies, viral capsid 
antigen, EBV nuclear antigens [EBNA-1 & 2], latent 
membrane proteins 1 & 2, EBV RNA-EBER-1 & 2 [EBV 
non-polyadenylated RNA’s], and microRNA’s), as well as 
lymphocytic markers (e.g., TIL, flow cytometric measures of 
CD23, CD30, CD39, CD58 & CD70, and ELISA of IL-10, 
all of which have been reported to rise in clinical and 
experimental models of EBV infection; 5,23,24), as well as 
DNA, RNA and chromatin signatures by a variety of 
protocols including serial analysis of gene expression 
(SAGE) (33).  Expectations are  that marker identification 
would be successfully carried out in body fluids local to the 
NpC tumors (i.e., whole, parotid sub-mandibular/sub-lingual 
saliva, sputum and expectorate, nasal discharge), as well as 
systemic fluids (i.e., serum, plasma, cerebrospinal fluids, 
thoracic lymph).  Histological and histopathological control 
verification would derive from assessment of normal tissues 
for signs of NpC risk, swab of oral mucosa, oro-pharynx, 
nasal and nasopharynx by means of DNA analysis, including 
culture/serological analysis of viral materials.  The auto-
proteomic protocol for EBV titers in body fluids, and 
immunohistochemical analyses for markers of mitosis (e.g., 
securin, survivin and MCM2 as in our glioma model), will 
then need to be supplemented by assessing viral particles and 
phospho-proteins (e.g., PI3K pathway, altered by ELMP2A, 
as noted above) [5, 11] in order to assess NpC occurrence 
and regression during treatment.  
 
Discussion:   
The recent advances in proteomics and its utilization to 
analyze blood, plasma, saliva and related body fluids are vital 
to the studies of cancer particularly in the search for 
biomarkers. These tools can now be harnessed to pre-empt 
the occurrence of cancer, particularly in high-risk patients 
with NpC, because this particular tumor is most often 
diagnosed after the disease has advanced to its later stages.  
When a mass in the neck first becomes evident, the cellular 
events of the cancer are substantial, and the tumor is likely to 
be metastasizing.  Thus, patient survival is curtailed.  The 
hypothetical proposition that molecular and epigenetic 
biomarkers, which we now have the capability to test and 
assess with reliable stringency in body readily accessible 
body fluids (e.g., saliva, [39]), may be used as likely 
informants for NpC early detection and monitoring of 
therapy outcome. 
 
Auto-proteomic approach towards biomarker discovery 
in NpC 
We propose here that NpC and related molecular and 
epigenetic signs during the transition of normal tissue to NpC 
must be picked up by proteomic protocols prior to gross 
tumor development and anatomical pathology, because of the 
inherently greater strength and sensitivity of molecular over 
traditional histological techniques. The rationale for our 
hypothesis rests on the awareness that fundamental 
physiological and pathological changes that become 
associated with disease occurrence are antecedent to tumor 
growth and metastasis. Furthermore, the increased reliability 
in proteomic mining of the body fluid proteome [25] leads us 
to infer that an auto-proteomic approach protocol may be 
essential for individuals at high-risks for NpC (e.g., based on 
genetic make-up, exposure history, diet). 
 
The auto-proteomic protocol (Scheme 2 in supplementary 
material) should provide a high-risk individual’s marker 
profile during the health period and before the tumor growth 
commences.  This initial “baseline” profile would then be 
compared at regular intervals, and tested for the emergence 
of proteomic markers suggesting the onset and presence of 
NpC. The regular update of the proteomic profile, the auto-
proteomic test of a high-risk subject will in this manner 
ensure personalized evidence-based medicine for NpC 
patients, prompt intervention, and reliable evaluation of the Bioinformation by Biomedical Informatics Publishing Group                                     open access 
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effectiveness of the treatment intervention. It is clear that the 
results we have obtained with our glioma model point to 
implications and applications specifically to the NpC case, as 
discussed here.  It is also evident that our hypothesis can be 
generalized to other cancers beyond NpC as well. 
 
A pragmatic objection to the model we propose queries what 
tissue ought to be tested and analyzed in subjects at high risk 
for NpC in order to optimize the panel of informant 
biomarkers.  We have submitted above that nasal sputum and 
nasal discharges ought to be tested, and we cited 
epidemiological data that point to African children, South-
Asian adults, and males preferentially as particularly high-
risk for NpC.  In an approach parallel to the analysis of nasal 
discharge and sputum for the monitoring of lung cancer [26-
28], we argue that the same body fluids and whole saliva 
could be among the tissues certainly of heightened value for 
NpC monitoring. The quantification of EBV materials and 
anti-EBV antibodies could be used as a normative value to 
suggest EBV-positivity and increased molecular and 
epigenetic propensity (i.e., immunohistochemistry, molecular 
mitotic profile) to developing NpC.  
 
We defend that saliva, nasal biopsy materials (e.g., by 
nasopharyngoscopy) for EBV, which has been implicated in 
the formation of Burkitt’s lymphoma, a tumor of the jaw 
common in African children [29], and for the NpC molecular 
signature should be scheduled bi-annually in high-risk 
individuals. This preventive protocol would be no different 
than the common recommendation of frequent colonoscopies 
annually for patients at high risk for colon cancer [30, 36].  
 
Translational personalized medicine approach for NpC 
patients 
Translational personalized evidence-based medicine should 
be followed through at the bench, and in the clinic. The 
ability to successful culture patient tumor samples [5], 
subject them to molecular analysis, run samples on western 
blot to probe with antibodies, or extract DNA and RNA from 
these samples for further assessment, including the use of 
laser micro-dissection to help isolate specific sites on the 
tumors to test, brings to us that high level of achieving 
molecular precision in personalized medicine. 
 
It ought to be possible to obtain gene expression profiles and 
proteomic signatures of a patient sample, normal vs. NpC 
tumor, in cell cultures subjected to EBV transformational 
materials or subjected to array of growth factors, as well as in 
ligands found in body fluids in vivo. Validated markers that 
result from this approach could be profiled for early detection 
of disease in the local and systemic body fluids.  Progress in 
saliva diagnostics, including the development of 
nanotechnology, afford point of care benefits [31], and have 
established that some degree of personalized medicine on the 
bench is highly informative in the context of translational 
evidence-based medical care in cancer diagnostics and 
prognostics. 
 
The hypothetical protocol we propose here, therefore, 
suggests that a personalized bench auto-proteomic approach 
should guide to an improved personalized clinical approach, 
which will strive to integrate the best available evidence, the 
clinic, and the bench in a true translational evidence-based 
medical diagnostic and practice paradigm. One limitation of 
our hypothesis is that the proposition will involve a large 
scale but unique molecular analysis of each patient tumor 
samples with NpC in a bid to specifically obtain proteomic 
and genetic profiles of each samples.  Taken together this 
information will be most valuable in that it will be collected 
into a single database. Expectations are that the pooling 
together of detailed molecular analysis-genes, proteins and 
RNA of a consistently rising number of NpC samples will 
permit a Baysian analysis aimed at revealing and validating 
statistically distinct biomarker signatures common to this 
tumor across ethnicities, genders and ages. 
 
The need for panel of biomarkers 
Oncology studies increasingly demonstrate the need to use 
multi-faceted panels of biomarkers for cancer detection, 
diagnosis and monitoring [32, 34]. Based on the rationale that 
NpC is not different than other tumor, we seek to develop a 
panel of biomarkers specific for NpC, which could serve at 
the level of prevention, early detection, high-risk detection, 
and assessment during therapy. The panel must be crafted at 
a level of detail that involves and incorporates looking at 
multiple factors including EBV positivity, epigenetic 
modulation of gene and chromatin architecture, assembly and 
repair, proteins and regulation of gene products (including 
RISC, the RNA inhibitory signaling complex, [38]), 
signaling pathways and related phospho-proteins, as well as 
the summative and subtractive effects of these biomarkers. 
 
For example, we venture that early detection of NpC might 
be revealed by a panel of biomarkers that will identify the 
EBV materials (e.g., latent proteins), PI3K-derived phospho-
proteins, and flow cytometric lymphocytic markers of EBV 
infection noted above. In our glioma model, we noted that 
tumors could be stratified by their gene profile into four 
molecular prognostic groups [22], and that these 
stratifications could serve to construct a panel of biomarkers 
with strong prognostic validity based gene voting and, by 
derivation, protein voting (cf., Figure 1a & 1b). The strength 
of our model was confirmed by a similar approach adopted in 
the case of blood cancers [35] in which “genes votes” were 
involved by weighting them together to help in the 
classification of leukemia. 
 
Voting among the panel of biomarkers in NpC 
Here, in the case of NpC, we propose that the same concept 
holds strong promise, and argue that if genes can “vote” to 
identify specific prognostic groups, then proteins must also 
cast be able to votes, which will soon apply to NpC 
proteomic biomarkers.  We now propose that, in the same 
fashion, we soon could have situations of “RNA voting”, and 
eventually genomic and epigenetic/chromatin voting.  
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It is very important in NpC and other cancers to interpret 
results of cancer molecular signatures as a whole before a 
detailed focus on a single signature. This holistic molecular 
approach could be described as the total gene votes, 
chromatin votes, RNA votes or protein votes of these 
signatures. This approach, which represents the direction of 
cancer diagnosis for the next decade of this XXI Century, 
help harness together the impact of events associated with 
NpC and other tumors.  It will provide insight into signaling 
pathway cross talks, suggest new therapeutic intervention or 
targets, allow for better ways to prevent tumor resistance to 
drugs, and provide signatures on ways of tumor recurrence 
and path of metastasis. 
 
Votes of genes, chromatin architecture, RNA or protein may 
be considered on the basis of those unique to a group or well 
defined cluster as in gliomas described above [22].  But, it 
can still be considered as “votes” of players across signaling 
pathways and different functional maps. Since cancer is an 
active interplay of many players, we are prepared to predict 
that a rigorous careful analysis of these votes will provide 
novel approaches to the management of NpC and other 
cancers in the near years to come. 
 
Conclusion: 
It is our expectation that NpC will have reduced occurrence if 
we develop the ability to identify aberrant changes in the 
normal anatomy, histology, physiology and fundamental 
biochemistry of the nasopharynx.  This goal can only be 
attained by the development and characterization of a pre-
emptive panel of biomarkers aimed at early detection for 
such cases that cannot be prevented, thereby ultimately 
leading to early diagnosis of NpC without obvious clinical 
signs or metastasis, and permissive of promising cure. 
Molecular analysis of tissues from nasal, nasopharyngeal, 
oral, oro-pharyngeal, saliva, blood and nasal sputum and 
discharges from individuals at high risk for NpC is timely 
and critical for improved detection and management of this 
cancer, and it promises to be for many other tumors.   
Physicians and pathologists are likely to be making better 
sustainable translational evidence-based clinical decisions if 
they rely on molecular signature data, which are typically 
more stringent, reliable and reproducible than other bench 
evidence. As molecular signatures are increasingly validated, 
and cancer tissue heterogeneity is streamlined by proteomic 
and related techniques, we envisage a time in the near future 
when  laser micro-dissection approaches will utilize these 
molecular signatures for directed, targeted  molecular 
intervention.  A proactive evolution of the traditional 
pathological reports will have personalized molecular maps 
supplement the habitudinal histopathology description.   
Together, histopathology, personalized molecular map, and 
auto-proteome assessment will converge to achieve well 
informed translational evidence-based therapeutic 
interventions optimized to ensure each patient’s benefit and 
treatment utility.  
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Supplementary Material 
 
Scheme 1A: -Profiling of the human proteome in health and disease. Schematic representation of the process that can be used 
to generate a human proteome database in health and disease. This approach will offer insight into diagnosis, cure and pre-
emptive approach to disease management. While it may appear cumbersome in outlook, major centers for tissue and disease 
specific proteome project may be established with a database to facilitate cross talk. Depending on the disease, age may be 
stratified by years as follows: (0-10, 11-20, 21-40, 41-60, >60). 
 
 
Scheme 1B: Cancer proteome approach. Schematic representation of the approach that could be used to search for valuable 
biomarkers in NpC cancer patients with a depository into a central cancer proteome database. Suggested stratification by race, 
sex and age are vital to unravel subtle differences of various cancer presentation, incidence and prevalence. Age may be stratified 
as follows in years (0-10,11-25,26-30,31-35,36-40,41-45,46-50,50-60,>60). Appropriate modifications may be needed for each 
type of cancer. 
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Scheme 1C: Approach to biomarkers-Cell line model. Schematic representation of the process that could serve for the search 
of biomarkers in cell lines. A designated center for cell line studies could be established to focus on several cancer cell lines. 
Various cytokines and growth factors (EGF, TGF, PDGF, and FGF) implicated in cancer could be evaluated with a standardized 
protocol; cells could be hit with multi-ligand to simulate the in vivo dynamics of the body. Possible targets of interests are listed 
and results obtained from such database could be validated or tested on human cancer tissues/fluids. 
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Scheme 2:  Schematic representation of the auto-proteome approach: Molecular proteomic profile of local body fluids or 
tissues can be easily assessed in high risks individuals over the period of normal health to the critical ages of development of 
NpC and beyond. This is assessed regularly annually, bi-annually or at intervals determined by the level of risks in a typical 
individual. This approach therefore establishes a personal proteomic profile which over time reduces molecular noise and 
presents with molecular signatures for a normal health or impending cancer. This allows for early tumor detection, increase 
survival and personalized medicine. This auto-proteomic approach could be use to profile systemic fluids likewise and applied to 
other cancer model.  